Merck & Company Buy Rating Justified by Keytruda’s Performance and Gardasil’s Market Potential
Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).
Seeking Alpha3d
Merck & Co., Inc. (MRK) Bank of America Global Healthcare Conference (Transcript)
We've seen -- we saw a compression of all the HPV vaccines in the second quarter. And there were three things highlighted. The one thing that I can focus on really is Zhifei. So you asked about Zhifei ...
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
The gross proceeds to the Company from the exercise of the Existing Warrants together with the sale of the new warrants is expected to be approximately $6.2 million. The closing of the transaction is ...
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Lipid Nanoparticles Market to Reach USD 350.5M by 2029 | MarketsandMarkets™
The global lipid nanoparticles market is expected to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, with a ...